Last reviewed · How we verify

NCT04730401: CP_COVID-19

Convalescent Plasma in the Treatment of Covid-19

Status unknown Phase 2 Last updated 7 July 2022
What this trial tests

Phase 2 trial testing Convalescent plasma from COVID-19 donors in Covid19 in 390 participants. Status unknown.

Timeline
27 January 2021
Primary endpoint
30 January 2022
30 January 2023

Quick facts

Lead sponsorHelsinki University Central Hospital
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment390
Start date27 January 2021
Primary completion30 January 2022
Estimated completion30 January 2023
Sites1 location across Finland

Drugs / interventions tested

Conditions studied

Sponsor

Helsinki University Central Hospital

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates the possible adverse effects and effectiveness of convalescent plasma for patients infected with SARS-CoV-2. Following provision of informed consent, patients will be randomized into three groups: High-titre convalescent plasma, low-titre convalescent plasma or placebo. Primary outcomes of the study will cover safety and either intubation or initiation of systemic corticosteroids. Safety information collected will include serious adverse events judged to be related to administration of convalescent plasma. Microbiological and other laboratory parameters will be followed up.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V, Iannizzi C, Chai KL, Valk SJ, et al · · 2021 · cited 106× · PMID 34013969 · DOI 10.1002/14651858.cd013600.pub4
  2. Convalescent plasma for people with COVID-19: a living systematic review.
    Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 24× · PMID 36734509 · DOI 10.1002/14651858.cd013600.pub5
  3. Convalescent plasma for people with COVID-19: a living systematic review.
    Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 21× · PMID 37162745 · DOI 10.1002/14651858.cd013600.pub6
  4. Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.
    Chavda VP, Bezbaruah R, Dolia S, Shah N, et al · · 2023 · cited 10× · PMID 36741339 · DOI 10.1016/j.procbio.2023.01.018
  5. Coagulation Profile of Convalescent Plasma Donors and Recipients.
    Pitkänen HH, Helin T, Khawaja T, Pietilä JP, et al · · 2025 · PMID 39886886 · DOI 10.1177/10760296251317522

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other Helsinki University Central Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04730401.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing